Home » Newsletters » BioWorld Science

BioWorld Science

April 13, 2011

View Archived Issues

Almac Discovery reports preclinical antiangiogenic activity for ALM-201

IND application filed for mTOR/PI3K-alpha inhibitor PWT-33597 based on in vivo antitumor action

Preclinical data provide support for GDC-0980 in phase I trials

Suven Life Sciences' histamine H3 receptor antagonist improves cognitive performance in vivo

Snapshots: New data on boceprevir in hepatitis C presented at EASL meeting

Janssen Pharma's new analgesics JNJ-40413269 and JNJ-40534832 show promise in vivo

Novel beta-lactamase inhibitors patented by Nabriva

GE Healthcare and Hammersmith Imanet present novel radiolabeled gallium complexes

Primary efficacy objective met in phase III GetGoal-S trial of lixisenatide in type 2 diabetes

First patient enrolled in phase II study of Zybrestat/bevacizumab in ovarian cancer

New inhibitors claimed of interaction between integrin alpha-4 and paxillin

New modulators of nicotinic acetylcholine alpha7 receptor claimed

NeuroSearch patents new monoamine uptake inhibitors for mood disorders

Novel modulator presented of metabotropic glutamate mGlu5 receptor

New modulators of voltage-gated calcium channels designed at Zalicus

Eteplirsen is approved as USAN name for AVI-4658

FDA committee votes in favor of Pfizer's Sutent in unresectable pancreatic NET

First patient treated in phase I TOPAS study of 4SC's selective HD inhibitor 4SC-202

Pieris and Daiichi Sankyo to collaborate on development of novel Anticalin therapeutics

Kyowa Hakko Kirin launches Romiplate in Japan for chronic ITP

Xiapex launched in E.U. for Dupuytren's contracture

FDA advisory committee recommends approval of Novartis' Afinitor for advanced pancreatic NET

Taiho and Helsinn sign agreement for netupitant/palonosetron fixed-dose combination in Japan

Immunovaccine reports interim phase I data on anticancer vaccine DPX-0907

PharmaMar begins phase II Yondelis trial in advanced breast cancer

Morphotek receives additional DOD funding to develop therapeutic mAbs against biowarfare agents

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 6, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
Cytospire raises £61M series A to target EGFR in solid tumors
BioWorld
Next-generation T-cell engager (TCE) specialist Cytospire Therapeutics Ltd. has raised £61 million (US$82.7 million) in a series A round, equipping it to advance...
Bio Korea 2026: US policy risks shift to execution framework
BioWorld
Regulatory uncertainty that dominated the life science sector in 2025 is transitioning into an execution framework for biotechnology companies, provided companies...
Regulatory actions for May 5, 2026
BioWorld
Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Adma, Applied...